BioSpace News Archive

Clover Biopharmaceuticals, Ltd., a global clinical-stage biotechnology company committed to developing novel vaccines and biologic therapeutic candidates, and CEPI, the Coalition for Epidemic Preparedness Innovations, announced that CEPI will provide up to an additional US$36.9 million in funding to support continued development of SCB-2019 through licensure.

CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid, announced the online publication of the extended preclinical study of the second-generation vaccine candidate, CV2CoV, jointly developed with GSK, in the journal Nature.

Thomas Powell, Executive Vice President and CFO, Teleflex Incorporated (NYSE: TFX), is pleased to participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference.

Caris Life Sciences® announced today that the Herbert Irving Comprehensive Cancer Center (HICCC) has joined Caris’ Precision Oncology Alliance™ (POA).

Epizyme, Inc. today announced two appointments to the Company’s Board of Directors: clinical oncology executive, Roy A. Beveridge, M.D., and international pharmaceutical and financial executive, Carol Stuckley, M.B.A.

Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, has announced it was named a winner in the MedReps.com Best Places to Work in Medical Sales 2022 survey, earning the Number 1 spot for large companies and making this the fifth consecutive year the company has been on the list.

Adicet Bio, Inc. today announced the appointment of Michael G. Kauffman, M.D., Ph.D., to its Board of Directors.

FDA Approves Merck’s KEYTRUDA ® (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery.

Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), today announced that John H. Sampson, MD, PhD, MHSc, MBA, Robert H. and Gloria Wilkins Distinguished Professor of Neurosurgery at Duke University School of Medicine and member of Medicenna’s Board of Directors, received The Abstract Award for Excellence in Clinical Trials in connection with an upcoming oral presentation on MDNA55.

PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics to improve surgical outcomes, announced today that the 500th patient has been enrolled into its ongoing Phase 3 SHIELD I study.